|
C1ORF83 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.69290026441615E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.89750043139748E-10 |
| Normal-vs-Stage2 |
3.6981000000047E-06 |
| Normal-vs-Stage3 |
2.0070944906081E-11 |
| Normal-vs-Stage4 |
6.20520301808369E-11 |
| Stage1-vs-Stage2 |
3.793800E-01 |
| Stage1-vs-Stage3 |
6.450200E-02 |
| Stage1-vs-Stage4 |
1.366040E-01 |
| Stage2-vs-Stage3 |
4.985900E-02 |
| Stage2-vs-Stage4 |
7.124000E-02 |
| Stage3-vs-Stage4 |
9.575400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.44730005757765E-10 |
| Normal-vs-AfricanAmerican |
8.53890000040991E-07 |
| Normal-vs-Asian |
2.99569999917537E-08 |
| Caucasian-vs-AfricanAmerican |
5.531600E-01 |
| Caucasian-vs-Asian |
9.440800E-01 |
| AfricanAmerican-vs-Asian |
5.836200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.35906866158575E-12 |
| Normal-vs-Female |
2.35579999952051E-10 |
| Male-vs-Female |
7.501600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.49399978236431E-10 |
| Normal-vs-Age(41-60Yrs) |
3.39700045870472E-10 |
| Normal-vs-Age(61-80Yrs) |
3.34769989507322E-10 |
| Normal-vs-Age(81-100Yrs) |
3.436600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.687200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.916200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.499000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.796200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.878000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.916600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.328210E-02 |
| Classical-VS-Follicular |
9.353800E-01 |
| Classical-VS-Other |
5.125600E-01 |
| Classical-VS-Normal |
3.89760002050821E-09 |
| Tall-VS-Follicular |
4.612500E-02 |
| Tall-VS-Other |
7.800200E-01 |
| Tall-VS-Normal |
6.98360258510888E-11 |
| Follicular-VS-Other |
5.917800E-01 |
| Follicular-VS-Normal |
3.13199999268932E-09 |
| Other-VS-Normal |
3.944600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.55397916756783E-12 |
| Normal-vs-N1 |
1.41600065006742E-11 |
| N0-vs-N1 |
1.018470E-02 |
|
|
